[Structure-activity relationships of histone deacetylase inhibitors].
Among those enzymes that regulate gene expression, histone deacetylases (HDACs) play important roles in cell cycles. Extensive studies were carried out in the field of HDACs and the applications of HDAC inhibitors (HDACIs) as chemotherapeutic interventions for diverse diseases. HDACIs have moved from laboratories to clinic uses. Huge bodies of related research results were well documented and dispersed in literature. According to our understanding, HDACIs can be broadly classified as hydroxamic acids, cyclic tetrapeptides, short chain fatty acids, benzamides and electrophilic ketones. Herein, we are going to review the design and their structure-activity relationships of HDACIs and according to their structural catalogs.
Tan
Yu-Mei
YM
Institute of Molecular Design and Drug Discovery, School of Pharmaceutical Science, Central South University, Changsha 410013, China.
Huang
Wen-Yuan
WY
Yu
Nie-Fang
NF
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D001549:Benzamides / Q000737:chemistry; D005227:Fatty Acids / Q000737:chemistry; D051548:Histone Acetyltransferases / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry; D015394:Molecular Structure; D010456:Peptides, Cyclic / Q000737:chemistry; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001549:Benzamides; D005227:Fatty Acids; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D010456:Peptides, Cyclic; D051548:Histone Acetyltransferases; D006655:Histone Deacetylases